Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Business Wire
- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline- ZL-1503 originated from Zai Lab’s in-house discovery and development engine SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an extended serum half-life. The dual targeting potentially provides faster onset of action and superior efficacy.In preclinical studies, ZL-1503 demonstrated the ability to simultaneously suppress inflammatory and pruritogenic (itch-causing) pathways imp
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Does Zai Lab's Steep 86.2% Slide Mask a Long Term Value Opportunity? [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces Updates to China's National Reimbursement Drug List [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces Updates to China’s National Reimbursement Drug ListBusiness Wire
- Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum [Yahoo! Finance]Yahoo! Finance
- Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) [Seeking Alpha]Seeking Alpha
ZLAB
Earnings
- 11/6/25 - Miss
ZLAB
Sec Filings
- 12/12/25 - Form 4
- 11/25/25 - Form 4
- 11/21/25 - Form 144
- ZLAB's page on the SEC website